Literature DB >> 23838466

Formulation and immunological evaluation of a trivalent vaccine comprising emulsified submicron particles and inactivated virions of H5N1/EV71/JEV.

Chih-Wei Lin1, Ching-Yun Chang, Wei-Lin Chen, Shih-Chang Lin, Chien-Chun Liao, Jui-Yuan Chang, Chia-Chyi Liu, Alan Yung-Chih Hu, Tsung-Chun Lu, Ai-Hsiang Chou, Suh-Chin Wu, Pele Chong, Ming-Hsi Huang.   

Abstract

Combination vaccines can reduce the number of injections and simplify the immunization schedule required to prevent different diseases. Here we assessed the immunogenicity in a mouse model of a vaccine composition comprising inactivated influenza viruses (H5N1/H1N1), enterovirus 71 (EV71), and/or Japanese encephalitis virus (JEV) and investigated whether the vaccine formulations can overcome the immunologic interference between the individual vaccine components. We demonstrated that the antigenic competition happens between H5N1/H1N1 or H5N1/EV71 inactivated virions when the vaccine combinations either formulated with Alum suspensions or without adjuvant. In the presence of PELC emulsified particles, EV71-specific immune responses before and after incorporating H5N1 virus into EV71 vaccine were detected of no significant difference; in addition, H5N1- and EV71-specific immune responses were found at the same level when H5N1/EV71/JEV consolidating into combination vaccine. Emulsified vaccine formulation was represented as a potential tool that is found to reduce the number of injections required to prevent multiple infectious strains causing the same disease (H5N1/H1N1) and/or that protect against different diseases (H5N1/EV71). Combination vaccines can also include a third component to protect against H5N1/EV71/JEV at the same time.

Entities:  

Keywords:  Japanese encephalitis; adjuvant; combination vaccine; enterovirus 71; influenza

Mesh:

Substances:

Year:  2013        PMID: 23838466      PMCID: PMC3981847          DOI: 10.4161/hv.25639

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  19 in total

1.  CD4+ T cells limit the damage in influenza.

Authors:  Anne Kelso
Journal:  Nat Med       Date:  2012-02-06       Impact factor: 53.440

2.  Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans.

Authors:  Tom M Wilkinson; Chris K F Li; Cecilia S C Chui; Arthur K Y Huang; Molly Perkins; Julia C Liebner; Rob Lambkin-Williams; Anthony Gilbert; John Oxford; Ben Nicholas; Karl J Staples; Tao Dong; Daniel C Douek; Andrew J McMichael; Xiao-Ning Xu
Journal:  Nat Med       Date:  2012-01-29       Impact factor: 53.440

Review 3.  The path to a successful vaccine adjuvant--'the long and winding road'.

Authors:  Derek T O'Hagan; Ennio De Gregorio
Journal:  Drug Discov Today       Date:  2009-03-05       Impact factor: 7.851

4.  The Madin-Darby canine kidney cell culture derived influenza A/H5N1 vaccine: a phase I trial in Taiwan.

Authors:  Sung-Ching Pan; Hsiang-Chi Kung; Tsui-Mai Kao; Hsio Wu; Shao-Xing Dong; Mei-Hua Hu; Ai-Hsiang Chou; Pele Chong; Szu-Min Hsieh; Shan-Chwen Chang
Journal:  J Microbiol Immunol Infect       Date:  2012-09-27       Impact factor: 4.399

5.  CpG DNA induces stronger immune responses with less toxicity than other adjuvants.

Authors:  R D Weeratna; M J McCluskie; Y Xu; H L Davis
Journal:  Vaccine       Date:  2000-03-06       Impact factor: 3.641

Review 6.  Multivalent vaccines: prospects and challenges.

Authors:  R E Spier
Journal:  Folia Microbiol (Praha)       Date:  1997       Impact factor: 2.629

7.  Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice.

Authors:  Ming-Hsi Huang; Su-Chen Lin; Chia-Hsin Hsiao; Hsin-Ju Chao; Hung-Ren Yang; Chien-Chun Liao; Po-Wei Chuang; Huang-Pi Wu; Chiung-Yi Huang; Chih-Hsiang Leng; Shih-Jen Liu; Hsin-Wei Chen; Ai-Hsiang Chou; Alan Yung-Chih Hu; Pele Chong
Journal:  PLoS One       Date:  2010-08-19       Impact factor: 3.240

8.  Enhancement of potent antibody and T-cell responses by a single-dose, novel nanoemulsion-formulated pandemic influenza vaccine.

Authors:  Ming-Hsi Huang; Chiung-Yi Huang; Su-Chen Lin; Jia-Huey Chen; Chien-Chun Ku; Ai-Hsiang Chou; Shih-Jen Liu; Hsin-Wei Chen; Pele Chong; Chih-Hsiang Leng
Journal:  Microbes Infect       Date:  2009-04-01       Impact factor: 2.700

9.  Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88.

Authors:  Anja Seubert; Samuele Calabro; Laura Santini; Barbara Galli; Alessia Genovese; Sara Valentini; Susanna Aprea; Annalisa Colaprico; Ugo D'Oro; Marzia M Giuliani; Michele Pallaoro; Mariagrazia Pizza; Derek T O'Hagan; Andreas Wack; Rino Rappuoli; Ennio De Gregorio
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-20       Impact factor: 11.205

10.  Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates.

Authors:  Ai-Hsiang Chou; Chia-Chyi Liu; Cheng-Peng Chang; Meng-Shin Guo; Shih-Yang Hsieh; Wen-Hsueh Yang; Hsin-Ju Chao; Chien-Long Wu; Ju-Lan Huang; Min-Shi Lee; Alan Yung-Chi Hu; Sue-Chen Lin; Yu-Yun Huang; Mei-Hua Hu; Yen-Hung Chow; Jen-Ron Chiang; Jui-Yuan Chang; Pele Chong
Journal:  PLoS One       Date:  2012-04-17       Impact factor: 3.240

View more
  2 in total

1.  Immunogenicity studies of bivalent inactivated virions of EV71/CVA16 formulated with submicron emulsion systems.

Authors:  Chih-Wei Lin; Chia-Chyi Liu; Tsung-Chun Lu; Shih-Jen Liu; Yen-Hung Chow; Pele Chong; Ming-Hsi Huang
Journal:  Biomed Res Int       Date:  2014-06-11       Impact factor: 3.411

2.  Emerging Hand Foot Mouth Disease in Bangladeshi Children- First Report of Rapid Appraisal on Pocket Outbreak: Clinico-epidemiological Perspective Implicating Public Health Emergency.

Authors:  Md Azraf Hossain Khan; Kazi Selim Anwar; A K M Muraduzzaman; Md Abid Hossain Mollah; S M Akhter-Ul-Alam; Kazi Munisul Islam; Sheikh Ariful Hoque; Md Nazrul Islam; Md Ahasan Ali
Journal:  F1000Res       Date:  2018-07-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.